Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Myasthenia Gravis and Recurrent Guillain-Barre Syndrome
Neurol 41:1848, Carlander,B.,et al, 1991
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Respiratory Management in Acute Neurologic Illness
Neurol 50:11-20, Wijdicks,E.F.M.&Borel,C.O., 1998
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990
Immunologic Aspects of Neurological & Neuromuscular Diseases
JAMA 258:2970-2973, Zweiman,B.&Arnason,B.G.W., 1987
Acute Bilateral Ophthalmoplegia:60 Cases
Neurol 36:279-281, Keane,J.R., 1986
Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972
Diseases of Muscles-Clinical Manifestations & Differential Diagnosis
The New Physic 263, 1967, Oct., Boshes,L., 1967
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation
JAMA Neurol 73:652-658,624, Bryant, A.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Incidence and Mortality Rates of Myasthenia Gravis and Myasthenic Crisis in US Hospitals
Neurol 72:1548-1554, Alshekhlee,A.,et al, 2009
Causes of Death Among Patients with Myasthenia Gravis in Norway Between 1951 and 2001
JNNP 77:203-207, Owe,J.F.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis
Arch Neurol 60:243-248, Kupersmith,M.J.,et al, 2003
Thymoma in Patients with MG
Neurol 59:1844-1850, Evoli,A.,et al, 2002
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
The Long-Term Clinical Outcome of Myasthenia Gravis in Patients with Thymoma
Neurol 51:1198-1200, Bril,V.,et al, 1998
Thymectomy for Myasthenia Gravis
Neurol 48 (Suppl 5) :S52-S63997., Jaretzki,A., 1997
Intensive Care of the Myasthenic Patient
Neurol 48 (Suppl 5) :S70-S75997., Mayer,S.A., 1997
Myasthenic Crisis:Clinical Features, Mortality, Comp, & Risk Factors for Prolonged Intubation
Neurol 48:1253-1254, Thomas,C.E.,et al, 1997
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Race, Sex, and Puberty Influence Onset, Severity, and Outcome in Juvenile Myasthenia Gravis
Neurol 44:1208-1214, Andrews,P.I.,et al, 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Ocular Myasthenia Gravis
J Natl Med Assoc 85:681-684, March,G.A.&Johnson,J.N., 1993
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
The Relationship of Age of Outcome in Myasthenia Gravis
Neurol 40:786-790, Donaldson,D.H.,et al, 1990
The Natural Course of Myasthenia Gravis:A Long Term Follow Up Study
JNNP 52:1121-1127, Oosterhuis,H.J.G., 1989